Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Envafolimab plus Chemotherapy in Gastric Adenocarcinoma
NCT05237349Phase 2Recruiting
- Start
- Mar 2022
- Primary completion
- Dec 2024
- Modality
- Nanobodies (VHH), Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of envafolimab in gastric adenocarcinoma. Primary endpoint: Objective Response Rate at 6 months. Started Mar 2022; status: recruiting.
02
Drugs
envafolimab
03
Conditions
gastric adenocarcinoma
Beyond the preview
Go deeper on NCT05237349.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05237349.